Abstract
Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatment to death or last visit available. Two hundred and sixty patients were included in this prospective study, aged 67 years, 60% with hepatitis C, 51% Child-Pugh A, 83% performance status (PS) ≥1, 41% with macroscopic vascular invasion, and 38% with extrahepatic tumor spread. Overall, median PSS was 4.1 (3.3-4.9) months, resulting from 4.6 (3.3-5.7) months for 123 progressors, 7.3 (6.0-10.0) months in 77 with adverse effects, and 1.8 (1.6-2.4) months in 60 decompensated patients (P
| Original language | English |
|---|---|
| Pages (from-to) | 784-791 |
| Number of pages | 8 |
| Journal | Hepatology |
| Volume | 62 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Sep 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Hepatology
- Medicine(all)
Cite this
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. / Iavarone, Massimo; Cabibbo, Giuseppe; Biolato, Marco; Della Corte, Cristina; Maida, Marcello; Barbara, Marco; Basso, Michele; Vavassori, Sara; Craxì, Antonio; Grieco, Antonio; Cammà, Carlo; Colombo, Massimo.
In: Hepatology, Vol. 62, No. 3, 01.09.2015, p. 784-791.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib
AU - Iavarone, Massimo
AU - Cabibbo, Giuseppe
AU - Biolato, Marco
AU - Della Corte, Cristina
AU - Maida, Marcello
AU - Barbara, Marco
AU - Basso, Michele
AU - Vavassori, Sara
AU - Craxì, Antonio
AU - Grieco, Antonio
AU - Cammà, Carlo
AU - Colombo, Massimo
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatment to death or last visit available. Two hundred and sixty patients were included in this prospective study, aged 67 years, 60% with hepatitis C, 51% Child-Pugh A, 83% performance status (PS) ≥1, 41% with macroscopic vascular invasion, and 38% with extrahepatic tumor spread. Overall, median PSS was 4.1 (3.3-4.9) months, resulting from 4.6 (3.3-5.7) months for 123 progressors, 7.3 (6.0-10.0) months in 77 with adverse effects, and 1.8 (1.6-2.4) months in 60 decompensated patients (P
AB - Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatment to death or last visit available. Two hundred and sixty patients were included in this prospective study, aged 67 years, 60% with hepatitis C, 51% Child-Pugh A, 83% performance status (PS) ≥1, 41% with macroscopic vascular invasion, and 38% with extrahepatic tumor spread. Overall, median PSS was 4.1 (3.3-4.9) months, resulting from 4.6 (3.3-5.7) months for 123 progressors, 7.3 (6.0-10.0) months in 77 with adverse effects, and 1.8 (1.6-2.4) months in 60 decompensated patients (P
UR - http://www.scopus.com/inward/record.url?scp=84939653557&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939653557&partnerID=8YFLogxK
U2 - 10.1002/hep.27729
DO - 10.1002/hep.27729
M3 - Article
C2 - 25645399
AN - SCOPUS:84939653557
VL - 62
SP - 784
EP - 791
JO - Hepatology
JF - Hepatology
SN - 0270-9139
IS - 3
ER -